Increasing cAMP Production in Response to Metformin-Induced GLP-1 and GIP MIN6 cells were treated with 10 nM GLP-1 or GIP in the presence of 5.5 or 16.7 mM glucose, and cAMP production was monitored for 40 min (Figures 1(a) and (b))
The list price is expected to be $1,000$1,500 per month, based on tirzepatide's pricing (~$1,060/month)
The clinical evidence base for this mechanism is robust: a peer-reviewed study in PLOS ONE confirming significant reductions in visceral adipose tissue with tesamorelin treatment compared to placebo across multiple patient populations supports the clinical rationale for using this peptide specifically for abdominal fat reduction
Injecting air creates positive pressure inside the vial that forces liquid back through the needle tract on subsequent draws, introducing contaminants that compromise sterility over the 28-day use window
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
